NanoMab Announces First Patient Dosed in Phase II Clinical Trial of Novel Radiolabelled Single Domain Antibody (NM-01) in Patients with Non-Small Cell Lung Cancer
info nano-mab2022-05-17T17:02:00+00:00London, May 17, 2022 - NanoMab Technology Limited, a privately held biopharmaceutical company focussing on the development of next generation radiopharmaceuticals for cancer precision therapies, today announced the dosing of the first patient in a phase II clinical trial in partnership with Lantheus and King’s College London. The phase II trial is a non-randomised, non-blinded, [...]